Orthocell Ltd (AU:OCC)
ASX:OCC
Want to see AU:OCC full AI Analyst Report?
OCC Stock Chart & Stats
AU$0.81
AU$0.07(4.58%)
At close: 4:00 PM EST
AU$0.81
AU$0.07(4.58%)
Day’s Range― - ―
52-Week RangeAU$0.70 - AU$1.60
Previous CloseN/A
Volume2.26M
Average Volume (3M)820.75K
Market Cap
AU$204.19M
Enterprise ValueAU$163.36M
Total Cash (Recent Filing)AU$44.37M
Total Debt (Recent Filing)AU$835.79K
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Aug 28, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding272,253,630
10 Day Avg. Volume747,972
30 Day Avg. Volume820,745
Financial Highlights & Ratios
PEG Ratio-3.76
Price to Book (P/B)18.08
Price to Sales (P/S)34.89
P/FCF Ratio-29.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.21Price Target Upside48.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$12.23M
Bulls Say, Bears Say
Bulls Say
Commercial Product And PipelineOrthocell already has a commercialised product (Remplir) plus a pipeline in regenerative medicine. That combination provides a current revenue base while R&D assets create durable upside if clinical development and market adoption progress, supporting multi-period growth.
Recurring Revenue GrowthReported revenue growth demonstrates durable top-line traction and increasing adoption of products or distribution reach. Sustained revenue expansion over multiple periods can support scale efficiencies, improve margin leverage, and justify continued investment in commercialization.
Conservative Capital StructureVery low financial leverage and a healthy equity base give the company flexibility to fund R&D and commercialization without heavy interest burdens. This conservative balance sheet reduces refinancing risk and supports strategic investments during multi-quarter commercialization phases.
Bears Say
Sustained UnprofitabilityPersistent negative margins and reported losses constrain internal funding for growth and increase reliance on external capital. Over several quarters this limits ability to reinvest, may dilute shareholders if funded by equity, and raises execution risk for commercial scaling.
Negative Operating Cash FlowOperating cash flow deficits mean day-to-day operations do not generate sufficient cash, forcing dependence on financing or reserves. This weak cash generation limits capacity to expand manufacturing, support sales channels, or sustain clinical programs without outside funding in the medium term.
Product Concentration RiskRevenue is concentrated around a single commercial product while other assets remain pre-commercial. That concentration makes medium-term performance highly sensitive to Remplir adoption, reimbursement and regulatory outcomes, raising structural execution and market-acceptance risk.
Orthocell Ltd News
OCC FAQ
What was Orthocell Ltd’s price range in the past 12 months?
Orthocell Ltd lowest share price was AU$0.70 and its highest was AU$1.60 in the past 12 months.
What is Orthocell Ltd’s market cap?
Orthocell Ltd’s market cap is AU$204.19M.
When is Orthocell Ltd’s upcoming earnings report date?
Orthocell Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 86 days.
How were Orthocell Ltd’s earnings last quarter?
Orthocell Ltd released its earnings results on Feb 23, 2026. The company reported -AU$0.021 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.021.
Is Orthocell Ltd overvalued?
According to Wall Street analysts Orthocell Ltd’s price is currently Undervalued.
Does Orthocell Ltd pay dividends?
Orthocell Ltd does not currently pay dividends.
What is Orthocell Ltd’s EPS estimate?
Orthocell Ltd’s EPS estimate is 0.
How many shares outstanding does Orthocell Ltd have?
Orthocell Ltd has 272,253,630 shares outstanding.
What happened to Orthocell Ltd’s price movement after its last earnings report?
Orthocell Ltd reported an EPS of -AU$0.021 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.333%.
Which hedge fund is a major shareholder of Orthocell Ltd?
Currently, no hedge funds are holding shares in AU:OCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orthocell Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.21 (48.77% Upside)
AU$1.21 (48.77% Upside)
Blogger Sentiment
Bullish
AU:OCC Sentiment 96%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$44.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.48%
12-Months-Change
Fundamentals
Return on Equity
-44.80%
Trailing 12-Months
Asset Growth
49.36%
Trailing 12-Months
Company Description
Orthocell Ltd
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental application; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
OCC Stock 12 Month Forecast
Average Price Target
AU$1.21
▲(48.77% Upside)
Technical Analysis
Cynata Therapeutics Limited
―
Living Cell Technologies
―
Mesoblast Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Options Prices
Currently, No data available
---